ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Amgen 

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


SEARCH JOBS




Collaborations

Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax Corp.  Antibody phage display





 Company News
Amgen (AMGN) Announces 30 Percent Increase In 2015 First Quarter Dividend 12/18/2014 8:30:52 AM
Amgen (AMGN)'s Blincyto To Carry A Hefty $178,000 Price Tag 12/17/2014 2:53:14 PM
Amgen (AMGN) And AstraZeneca PLC (AZN) To Present Results From Phase 3 AMAGINE-1 Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 12/12/2014 7:32:55 AM
Amgen (AMGN) Wins FDA Approval For New XGEVA Indication 12/9/2014 7:25:46 AM
Amgen (AMGN) Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 12/9/2014 7:11:36 AM
New Trial Initiated Evaluating Amgen (AMGN)'s Talimogene Laherparepvec In Combination With Merck & Co. (MRK)'s Anti-PD-1 Therapy KEYTRUDA (Pembrolizumab) For Advanced Melanoma 12/9/2014 7:08:36 AM
FDA Approves Amgen (AMGN)'s XGEVA (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy 12/8/2014 9:12:23 AM
Amarantus BioSciences, Inc. Appoints Renowned Drug Development Expert And Co-Founder Of Amgen (AMGN), Joseph Rubinfeld, Ph.D., To Its Board Of Directors 12/8/2014 8:37:52 AM
Amgen (AMGN) Announces New Data From Phase 2 BLINCYTO (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 12/8/2014 7:32:57 AM
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014 6:12:14 AM
12345678910...